Navigation Links
Impax Pharmaceuticals Selects OmniComm Systems to Provide eClinical Solutions for International Phase III Study in Parkinson's Disease
Date:8/20/2009

FORT LAUDERDALE, Fla., Aug. 20 /PRNewswire-FirstCall/ -- OmniComm Systems, Inc. (OTC Bulletin Board: OMCM), one of the fastest growing companies in the EDC marketplace, today announced that Impax Pharmaceuticals, the brand division of Impax Laboratories, Inc., Hayward, CA, has selected the TrialMaster EDC solution for conducting a Phase III study in patients with Parkinson's Disease. "While managing a global multi site clinical trial there can be significant challenges in getting trial data when you want it and in the format that you need it," said Suneel Gupta, PhD, Chief Scientific Officer for Impax. "The TrialMaster EDC solution provides us with an intuitive and easy to use export tool that simplifies the process. After considering multiple different EDC solutions, we selected OmniComm Systems based on its customer driven approach and reputation for delivering unparalleled service and support. Additionally, its support of industry standards has enabled us to meet our very tight corporate timelines for this important study."

"We look forward to working with Impax to assist them in the fight to cure Parkinson's disease," remarked Stephen Johnson, COO of OmniComm Systems. "We are honored that after an extensive evaluation, OmniComm's electronic data capture solution, TrialMaster(TM), was chosen to capture and process their clinical trial data. TrialMaster(TM) will enable them to continue to make informed and strategic decisions that will be vital to their success as a company."

About Impax Laboratories, Inc.

Impax Laboratories, Inc. is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of branded products. Impax markets its generic products through its Global Pharmaceuticals division and markets its branded products through the Impax Pharmaceuticals division. Additionally, where strategically appropriate, Impax has developed marketing partnerships to fully leverage its technology platform. Impax Laboratories is headquartered in Hayward, California, and has a full range of capabilities in its Hayward and Philadelphia facilities. For more information, please visit the Company's Web site at: www.impaxlabs.com.

About OmniComm

OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's client intuitive pricing model allows companies that range from small, to mid-size to large scale institutions to safely and efficiently capitalize on their clinical research investments. OmniComm Systems, Inc. has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey, the United Kingdom, and Russia as well as sales offices throughout the U.S. and Europe.

Safe Harbor Disclaimer

Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

    CONTACT:
    Catherine Lemercier                      Gary Nash
    OmniComm Systems, Inc.                   CEOcast, Inc. for OmniComm
    954-377-1728                             212-732-4300
    clemercier@omnicomm.com                  gnash@ceocast.com

    Stephen Johnson at: + 1 954-377-1726


'/>"/>
SOURCE OmniComm Systems, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Amira Pharmaceuticals Submits IND for Second DP2 Antagonist, AM461
2. Adamas Pharmaceuticals Signs CRADA With U.S. Navy to Conduct Preclinical Studies of Triple-Combination Antiviral Drug Therapy for Influenza A, Including the Novel H1N1 Pandemic Strain
3. Eiger BioPharmaceuticals Announces Initiation of CLEAN-1 HCV Phase 1b Trial
4. Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program
5. Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing
6. Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
7. Cardax Pharmaceuticals Nominates Clinical Candidate Heptax for Liver Disease; Heptax Ameliorates Inflammation and Oxidative Stress Related to Liver Disease and Metabolic Syndrome
8. BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza
9. Tibotec Pharmaceuticals Announces Agreement to Develop and Commercialize a New Fixed-Dose Combination of TMC278 and Truvada(R) With Gilead Sciences
10. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
11. Bioniche Life Sciences Inc. and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... Aug. 15, 2017  AOTI Inc. announced today that its fully ... has recently opened a New York City Office in ... its unique Topical Wound Oxygen (TWO 2 ) homecare therapy. This ... Commission for Health Care (ACHC) under the company,s DMEPOS accreditation for ... ...
(Date:8/8/2017)... -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused ... for the second quarter ended June 30, 2017. ... and to date: ... Company,s lead project, BL-8040: Announced plans ... novel stem cell mobilization treatment for autologous bone-marrow transplantation ...
(Date:8/7/2017)... , Aug. 7, 2017 Diplomat Pharmacy, Inc. (NYSE: ... Joel Saban as president, effective Aug. 7, 2017. ... has decided to pursue other interests and will serve as ... tenure, Paul has served us in multiple leadership roles since ... in Jun. 2015 and has provided decisive, strategic leadership which ...
Breaking Medicine Technology:
(Date:8/21/2017)... ... ... PracticeMatch, a company that provides online resources , job boards ... like nurse practitioners and physician assistants , will conduct its first ... The online career fairs will allow job seekers to connect with healthcare employers from ...
(Date:8/21/2017)... (PRWEB) , ... August 21, 2017 , ... FCPX LUT ... Editors can quickly and easily add washed color grades to footage. A LUT ... LUT changes every pixel’s color to the corresponding color indicated by the table. This ...
(Date:8/21/2017)... (PRWEB) , ... August 21, 2017 , ... ... widely recognized community involvement program serving the people of Michigan. The new initiative ... almost 120 years at the very forefront of animal protection and welfare by ...
(Date:8/21/2017)... ... August 21, 2017 , ... San Diego physician and surgeon Dr. James Veltmeyer, ... announced his candidacy for the 52nd Congressional District currently held by Representative Scott Peters. ... to this country at age eleven after suffering homelessness and hardship in a distant ...
(Date:8/20/2017)... ... August 20, 2017 , ... HIPAA Solutions, ... System has assisted multiple clients in successfully passing audits such as Office ... Level 2 (AICPA SOC Level 2), and State Data Use Agreement Audits. ...
Breaking Medicine News(10 mins):